Pcn350 - Evaluation of Disease-Specific Skin Symptom Items on Skindex-29 in Cutaneous T-Cell Lymphoma Patients Treated With Mogamulizumab or Vorinostat

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.432
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Orphan Designation: Mogamulizumab, Treatment of Cutaneous T-Cell Lymphoma

Case Medical Research
2019English

Benefits of Vorinostat in Treating Advanced Cutaneous T-Cell Lymphoma

Oncology & Hematology Review (US)
2009English

Trends in the Treatment of Cutaneous T-Cell Lymphoma &Ndash; Critical Evaluation and Perspectives on Vorinostat

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Menus for Managing Patients With Cutaneous T-Cell Lymphoma

Seminars in Cutaneous Medicine and Surgery
DermatologyMedicineSurgery
2012English

LB1550 Skin Commensals as Instigators of Cutaneous T Cell Lymphoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2018English

Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

Archives of Dermatology
2009English

Cutaneous T-Cell Lymphoma With Nasal Necrosis

Archives of Plastic Surgery
Surgery
2015English

Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated With Disease Progression

Clinical Cancer Research
Cancer ResearchOncology
2019English

Anti-Ccr4 Monoclonal Antibody KW-0761 (Mogamulizumab) or Investigator's Choice in Subjects With Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma (ATL)

Retrovirology
VirologyInfectious Diseases
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy